Trial Profile
An Open Label Study of the Safety and Efficacy of Psilocybin in Participants With Treatment-Resistant Depression (P-TRD)
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 21 Dec 2022
Price :
$35
*
At a glance
- Drugs Psilocybin (Primary)
- Indications Major depressive disorder
- Focus Therapeutic Use
- 16 Dec 2022 Status changed from recruiting to active, no longer recruiting.
- 24 Oct 2022 Planned number of patients changed from 216 to 27.
- 24 Oct 2022 Planned End Date changed from 1 Apr 2022 to 24 Oct 2023.